JP2017012144A5 - - Google Patents

Download PDF

Info

Publication number
JP2017012144A5
JP2017012144A5 JP2015200708A JP2015200708A JP2017012144A5 JP 2017012144 A5 JP2017012144 A5 JP 2017012144A5 JP 2015200708 A JP2015200708 A JP 2015200708A JP 2015200708 A JP2015200708 A JP 2015200708A JP 2017012144 A5 JP2017012144 A5 JP 2017012144A5
Authority
JP
Japan
Prior art keywords
vitamin
composition according
citrulline
active ingredients
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015200708A
Other languages
Japanese (ja)
Other versions
JP2017012144A (en
JP6584270B2 (en
Filing date
Publication date
Application filed filed Critical
Priority to JP2015200708A priority Critical patent/JP6584270B2/en
Priority claimed from JP2015200708A external-priority patent/JP6584270B2/en
Publication of JP2017012144A publication Critical patent/JP2017012144A/en
Publication of JP2017012144A5 publication Critical patent/JP2017012144A5/ja
Application granted granted Critical
Publication of JP6584270B2 publication Critical patent/JP6584270B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (5)

シトルリンと、下記（ａ）〜（ｅ）からなる群より選ばれる少なくとも１種の成分とを有効成分として含有することを特徴とする組成物。
（ａ）黒ショウガ、ショウガ、コショウ、稲、及びマキベリーから選ばれる少なくとも１種の植物素材
（ｂ）麦芽糖、トレハロース、還元パラチノース、還元麦芽糖、ステアリン酸カルシウム、及びシェラックから選ばれる少なくとも１種の機能性添加剤
（ｃ）ロイシン、メチオニン、フェニルアラニン、プロリン、セリン、トレオニン、トリプトファン、チロシン、及びバリンから選ばれる少なくとも１種のアミノ酸
（ｄ）没食子酸
（ｅ）ビタミンＡ、ビタミンＢ１、ビタミンＢ２、ビタミンＣ、パントテン酸ナトリウム、ナイアシン、葉酸、ビオチン、ビタミンＫ、イノシトール、カルシウム、亜鉛、鉄、銅、セレン、モリブデン、マグネシウム、及びクロムから選ばれる少なくとも１種のビタミン・ミネラル類 A composition comprising citrulline and at least one component selected from the group consisting of the following (a) to (e) as active ingredients.
(A) at least one plant material selected from black ginger, ginger, pepper , rice, and maquiberry (b) at least one functionality selected from maltose, trehalose, reduced palatinose, reduced maltose, calcium stearate, and shellac Additive (c) At least one amino acid selected from leucine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine (d) gallic acid (e) vitamin A, vitamin B1, vitamin B2, vitamin C At least one vitamin or mineral selected from sodium pantothenate, niacin, folic acid, biotin, vitamin K, inositol, calcium, zinc, iron, copper, selenium, molybdenum, magnesium, and chromium シトルリンと（ａ）〜（ｅ）からなる群より選ばれる少なくとも１種の成分とからなる有効成分を添加して得たことを特徴とする請求項１記載の組成物。   The composition according to claim 1, obtained by adding an active ingredient comprising citrulline and at least one component selected from the group consisting of (a) to (e). シトルリン及び他の有効成分の配合質量比が、０．５：１〜７０：１の範囲であることを特徴とする請求項１又は２記載の組成物。   The composition according to claim 1 or 2, wherein the blending mass ratio of citrulline and other active ingredients is in the range of 0.5: 1 to 70: 1. 錠剤、カプセル剤、粉末剤、顆粒剤、又は液剤であることを特徴とする請求項１〜３のいずれか記載の組成物。   The composition according to any one of claims 1 to 3, which is a tablet, capsule, powder, granule, or liquid. 請求項１〜４のいずれか記載の組成物を摂取させることを特徴とする血流改善方法（ただし、医療行為を除く）。   A method for improving blood flow, wherein the composition according to any one of claims 1 to 4 is ingested (excluding medical practice).
JP2015200708A 2015-10-09 2015-10-09 Blood flow improving composition Active JP6584270B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2015200708A JP6584270B2 (en) 2015-10-09 2015-10-09 Blood flow improving composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2015200708A JP6584270B2 (en) 2015-10-09 2015-10-09 Blood flow improving composition

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015133936A Division JP5888574B1 (en) 2015-07-02 2015-07-02 Blood flow improver

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019158789A Division JP6838752B2 (en) 2019-08-30 2019-08-30 Blood flow improving composition

Publications (3)

Publication Number Publication Date
JP2017012144A JP2017012144A (en) 2017-01-19
JP2017012144A5 true JP2017012144A5 (en) 2019-03-14
JP6584270B2 JP6584270B2 (en) 2019-10-02

Family

ID=57827326

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015200708A Active JP6584270B2 (en) 2015-10-09 2015-10-09 Blood flow improving composition

Country Status (1)

Country Link
JP (1) JP6584270B2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2685324B1 (en) * 2017-03-30 2019-07-22 Phidinut S L Pharmaceutical composition or nutritional supplement for the prevention and / or treatment of dry eye
JP6484774B1 (en) * 2017-11-30 2019-03-20 株式会社東洋新薬 Oral composition
WO2019117702A1 (en) * 2017-12-16 2019-06-20 Kam Faii Yuen A medicament to control and reduce hypertension
JP6484776B1 (en) * 2018-06-26 2019-03-20 株式会社東洋新薬 Oral composition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008253148A (en) * 2007-03-30 2008-10-23 Naris Cosmetics Co Ltd Food composition having poor circulation ameliorating function
JP2009067731A (en) * 2007-09-14 2009-04-02 Office K:Kk Composition for improving cold constitution
JP5921143B2 (en) * 2011-10-27 2016-05-24 株式会社ヤクルト本社 Flavor improving agent for beverages containing ginger
JP2013237629A (en) * 2012-05-14 2013-11-28 Oriza Yuka Kk Peripheral blood circulation disorder improving agent
JP6064156B2 (en) * 2012-07-10 2017-01-25 株式会社東洋新薬 Deep body temperature raising agent

Similar Documents

Publication Publication Date Title
PH12018502268A1 (en) Amide-substituted pyridinyltriazole derivatives and uses thereof
MX2018001721A (en) 5-bromo-2,6-di-(lh-pyrazol-l-yl)pyrimidin-4-amine for use in the treatment of cancer.
JP2017012144A5 (en)
WO2017100726A8 (en) Methods for treating huntington's disease
PH12016501310A1 (en) Pharmaceutical compositions comprising azd9291
MY161088A (en) Agonists of gpr40
MX2019003363A (en) Pharmaceutical compositions for use in the therapy of blepharitis.
MX2015017435A (en) Crystalline bromodomain inhibitors.
EA201101192A1 (en) PHARMACEUTICAL COMPOSITION, INCLUDING DERIVATIVES GLUCOPIRANZYDHYPHENILMETHANE, PHARMACEUTICAL DOSED FORM, CONTAINING INDICATED DERIVATIVES, METHOD OF THEIR RECEIVING APPLICATIONS
WO2017218981A3 (en) Compositions and methods for reducing ocular neovascularization
MX2018003926A (en) Composition for improved performance.
WO2019023039A3 (en) Compositions for enhancing bioavailability of pharmaceuticals, supplements and ingested substances
PH12017500159A1 (en) [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases
BR112015029773A2 (en) aroma coated powders
WO2016140933A3 (en) Immediate release soluble ibuprofen compositions
JP2017014155A5 (en)
JP2016210757A5 (en)
WO2016178510A3 (en) Pharmaceutical composition for preventing or treating gleevec-resistant leukemia, containing, as active ingredient, ginsenoside f1 or rg3
JP2017008001A5 (en)
MX2022006741A (en) Hdac inhibitor solid state forms.
WO2015001541A3 (en) Pharmaceutical film composition
JP2016216373A5 (en)
JP2017002009A5 (en)
WO2015044961A3 (en) Pharmaceutical composition comprising capecitabine and cyclophosphamide
JP2017014164A5 (en)